TA
LFCR icon

Tactive Advisors’s Lifecore Biomedical LFCR Stock Holding History

Tactive Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,402
Closed -$121K – 268
2025
Q3 		$121K Buy
16,402
+907
+6% +$6.86K 0.03% 240
2025
Q2 		$126K Buy
+15,495
New +$104K 0.04% 217

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Tactive Advisors's LFCR Position: Q4 2025 in Review

Tactive Advisors sold out of Lifecore Biomedical (LFCR) in Q4 2025, closing a stake of 16,402 shares — an estimated $121K sold.

Tactive Advisors first reported a position in LFCR in Q2 2025 and held it in 2 quarters. The position peaked at $126K in Q2 2025. 103 funds tracked by Wall St. Rank hold LFCR as of Q4 2025.

  • Tactive Advisors reported no remaining Lifecore Biomedical position as of Q4 2025 after selling out during the quarter.
  • Tactive Advisors sold 16,402 Lifecore Biomedical shares in Q4 2025, an estimated $121K.
  • Tactive Advisors first reported a position in Lifecore Biomedical in Q2 2025 and held it in 2 quarters.
  • Tactive Advisors's Lifecore Biomedical position peaked at $126K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2025.

Based on Tactive Advisors's 13F filing for Q4 2025, filed 9 Jan 2026.